IB Announces Soft Close to Phase 1 Trial

Imaging Biometrics Announces Soft Close to Phase 1 Trial of Oral Gallium Maltolate for Relapsed or Refractory Glioblastoma

Elm Grove, WI - July 21, 2025 - Imaging Biometrics, LLC, a leader in quantitative imaging and novel therapeutics for CNS malignancies, today announces a soft close to its Phase 1 clinical trial of oral gallium maltolate (GaM) in adult relapsed or refractory glioblastoma. The trial remains active for currently enrolled participants, with no additional patients being recruited at this time.

This milestone reflects strong early engagement and sufficient enrollment to meet the trial's statistical and operational objectives. While final internal approvals from the Medical College of Wisconsin Cancer Center are pending, the soft close enables the trial team to transition toward data consolidation, endpoint analysis, and Phase 2 protocol finalization - key steps in advancing the development of oral GaM.

Oral GaM offers a differentiated therapeutic profile: once-daily, at-home dosing, a favorable safety record, and a novel mechanism of action that disrupts iron metabolism in tumor cells. With excellent tolerability, GaM is positioned as a potentially transformative agent in glioblastoma care.

IB is actively evaluating the feasibility of independently financing the phase 2 trial while concurrently exploring strategic partnerships. The Company will provide further updates as the trial progresses toward formal closure and data dissemination.

The Board thanks its investigators, its collaborators at the Medical College of Wisconsin, and the patients who continue to drive this research forward.

The Directors of the Company accept responsibility for the contents of this announcement.